Interview with Jean-Pierre Delwart, Chief Executive Officer, Eurogentec Belgium
Mr Delwart, you have been acting CEO of EuroGenTec for an impressive 19 years. During your tenure, what would you say has been the single most important change in the…
Address: Rue du Bois Saint Jean, 5, 4102 Seraing,Belgium
Tel: +32 4 372 74 00
Web: http://www.eurogentec.com/eu-home.html
Eurogentec S.A., part of Kaneka Corporation, is a leading global supplier of innovative reagents, kits, specialty products and custom services. Through its three inter-related business units (BU), the company provides high quality products to scientists involved in the life science, biotechnology, diagnostic and pharmaceutical markets. Eurogentec is fully ISO 9001, ISO 13485 certified, cGMP accredited by the Belgian Ministry of Health and approved by the US FDA for the commercial manufacturing of a biologic for the US market.
The Life Science Research BU is specialized in innovative solutions in Genomics and Proteomics. Expert in small and large-scale synthesis, Eurogentec proposes a wide range of reagents, kits and consumables for Life Science applications such as Custom Oligonucleotides, high performance PCR/qPCR Kits & Reagents (including high pure Diamond Taq® DNA Polymerases), catalogue dyes, peptides & antibodies. Eurogentec is also specialist in the design and synthesis of custom peptides and production of custom antibodies (including a 28-day Speedy protocol) as well as producing pre-dispensed assays in a GMP environment.
The In Vitro Diagnostics BU provides technical and project support for contract manufacturing of GMP oligonucleotides and Taq DNA polymerases for use in Molecular Diagnostic applications. As a certified ISO 13485 and GMP compliant manufacturer, our manufacturing processes take place in classified clean rooms with controlled processes and full traceability. Our production facilities in Belgium and US enable high quality materials for the in vitro Diagnostic community.
The GMP BioManufacturing BU is a full-service Contract Manufacturing Organization (CMO) and offers significant know-how in process development, technology transfer, formulation, scale-up and manufacturing of GMP proteins, protein conjugates, plasmids and bacterial vaccines for pre-clinical, clinical and commercial uses, all according to FDA and EMA requirements. Experts in microbial production (E. coli, P. pastoris, etc), Eurogentec offers various development strategies based on protein refolding, periplasmic expression, and protein expression by secretion. As a one-stop shop, Eurogentec provides a complete gene to injectable service offering.
Mr Delwart, you have been acting CEO of EuroGenTec for an impressive 19 years. During your tenure, what would you say has been the single most important change in the…
Rainer Westermann offers a sobering take on Europe’s declining global status as both a source and recipient of biopharmaceutical innovation. He argues that the time for a paradigm shift in…
Writing in the January 2026 edition of DIA’s Global Forum, Samantha Holmes and Fiona Adshead of the Sustainable Healthcare Coalition argue that climate change is already reshaping healthcare and the…
The EU’s Health Technology Assessment Regulation (HTAR), which kicked off in January 2025, has launched joint clinical assessments (JCAs) for oncology and advanced therapies; yet six months in, implementation remains…
The latest stories from healthcare and the life sciences in Belgium, the Netherlands and Luxembourg (BeNeLux). UCB is considering a USD five billion investment in the US to avoid President…
Lora Fleifel, Director of Global Value Access & Pricing Operations Europe for Oncology at Merck, dissects the promise and pitfalls of the new EU Joint Clinical Assessment (JCA). The JCA…
To address the European Union’s drop in global share of clinical trials over the past decade, stakeholders are working together to deliver a dynamic, agile, responsive EU clinical trials environment.…
Will a new ‘Critical Medicines Act’ go far enough to ensure Europe’s resilience to future health crises? A Continent at Risk The COVID-19 pandemic exposed serious vulnerabilities in the…
The EMA’s Pre-Accession Assistance Program (IPA) helps EU candidate and potential candidate countries align their medicines regulations with EU standards through training, capacity-building, and policy support. As a new op-ed…
The European Brain Council (EBC) is a key player in advancing brain health research and policy across Europe, bringing together diverse voices to address the pressing issues of neurological and…
James Riddle of Advarra, writing in the January 2025 edition of DIA’s Global Forum magazine, looks at how the EU’s AI Regulation will impact clinical trials in Europe. In…
Last year the European Commission (EC) came out with a proposal to reform the EU’s core pharmaceutical legislation, aiming to address affordability, accessibility, and availability, among other objectives. One of…
Vikas Krishan, chief digital business officer at the global data and digital engineering solutions firm Altimetrik, outlines the implications of the European Union’s forthcoming AI Act for the pharma industry…
See our Cookie Privacy Policy Here
